HUTCHMED (China) Limited(HCM)Earnings, Financials & Key Ratios
HCM•NASDAQ
4.0× P/E·Price updated Jun 19, 2026
AboutHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.Show more
- Revenue$550M-12.7%
- EBITDA-$41M-31.9%
- Net Income$458M+1114.2%
- EPS (Diluted)2.60+1081.8%
- Gross Margin38.68%-13.4%
- EBITDA Margin-7.52%-51.2%
- Operating Margin-9.95%-43.5%
- Net Margin83.3%+1291.4%
- ROE45.29%+809.4%
HCM Key Insights
HUTCHMED (China) Limited (HCM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 21.6%
- ✓Strong 5Y sales CAGR of 19.3%
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HCM Price & Volume
HUTCHMED (China) Limited (HCM) stock price & volume — 10-year historical chart
Loading chart...
HCM Growth Metrics
HUTCHMED (China) Limited (HCM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.93%
5 Years19.26%
3 Years8.85%
TTM-1.41%
Profit CAGR
10 Years49.91%
5 Years-
3 Years-
TTM1212.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1165.87%
Return on Capital
10 Years-23.41%
5 Years-18.96%
3 Years-2.42%
Last Year-4.69%
HCM Recent Earnings
HUTCHMED (China) Limited (HCM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (67%)●Beat Revenue 1/12 qtrs (17%)
Q2 2026Latest
Mar 5, 2026Metric
Actual
Est
EPS
—
$2.50
Rev
$271M-6.7%
$291M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.30-11.0%
$1.46
Rev
$139M-58.0%
$330M
Q3 2025
Jul 2, 2025Metric
Actual
Est
EPS
$1.30
—
Rev
$139M
—
Q2 2025
Mar 19, 2025Metric
Actual
Est
EPS
$0.03+137.9%
$0.09
Rev
$162M-49.2%
$319M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | —vs $2.50 | $271Mvs $291M-6.7% |
| Q3 2025 | Aug 7, 2025 | $1.30vs $1.46-11.0% | $139Mvs $330M-58.0% |
| Q3 2025 | Jul 2, 2025 | $1.30 | $139M |
| Q2 2025 | Mar 19, 2025 | $0.03vs $0.09+137.9% | $162Mvs $319M-49.2% |
Based on last 12 quarters of dataView full earnings history →
HCM Peer Comparison
HUTCHMED (China) Limited (HCM) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZLAB | 2.01B | 18.18 | -11.36 | 15.33% | -39.29% | -24.32% | 0.31 | |
 LEGN | 5.17B | 27.93 | -17.46 | 64.04% | -21.97% | -24.91% | 0.41 | |
 CAN | 208.5M | 0.33 | -0.73 | 96.69% | -39.68% | -60.72% | 0.13 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 |
Compare HCM vs Peers
HUTCHMED (China) Limited (HCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HCM Income Statement
HUTCHMED (China) Limited (HCM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 241.2M | 214.11M | 204.89M | 227.98M | 356.13M | 426.41M | 838M | 630.2M | 549.96M | 602.2M |
Revenue Growth % | 11.63% | -11.23% | -4.31% | 11.27% | 56.21% | 19.73% | 96.52% | -24.8% | -12.73% | -1.41% |
Cost of Goods Sold | 175.82M | 143.94M | 160.15M | 188.52M | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M | 548.43M |
COGS % of Revenue | 72.89% | 67.23% | 78.16% | 82.69% | 72.51% | 72.96% | 45.88% | 55.36% | 61.32% | - |
Gross Profit | 65.38M▲ 0% | 70.17M▲ 7.3% | 44.74M▼ 36.2% | 39.46M▼ 11.8% | 97.89M▲ 148.1% | 115.31M▲ 17.8% | 453.55M▲ 293.3% | 281.32M▼ 38.0% | 212.72M▼ 24.4% | 53.76M▲ 0% |
Gross Margin % | 27.11% | 32.77% | 21.84% | 17.31% | 27.49% | 27.04% | 54.12% | 44.64% | 38.68% | 8.93% |
Gross Profit Growth % | 9.42% | 7.31% | -36.24% | -11.8% | 148.1% | 17.79% | 293.35% | -37.97% | -24.38% | - |
Operating Expenses | 118.8M | 162.81M | 197.26M | 236.13M | 426.21M | 523M | 436.23M | 321.93M | 267.45M | 73.46M |
OpEx % of Revenue | 49.25% | 76.04% | 96.27% | 103.57% | 119.68% | 122.65% | 52.06% | 51.08% | 48.63% | - |
Selling, General & Admin | 43.28M | 48.65M | 52.93M | 61.35M | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M | 96.73M |
SG&A % of Revenue | 17.94% | 22.72% | 25.84% | 26.91% | 35.7% | 31.92% | 15.89% | 17.92% | 18.78% | - |
Research & Development | 75.78M | 115.58M | 91.94M | 111.23M | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M | 190.1M |
R&D % of Revenue | 31.42% | 53.98% | 44.87% | 48.79% | 58.25% | 62.75% | 36.16% | 33.86% | 29.85% | - |
Other Operating Expenses | -256.26K | -1.42M | 52.38M | 63.54M | 91.64M | 119.31M | 0 | -4.35M | 0 | -2M |
Operating Income | -53.42M▲ 0% | -92.64M▼ 73.4% | -152.78M▼ 64.9% | -198.62M▼ 30.0% | -328.32M▼ 65.3% | -409.77M▼ 24.8% | 18.38M▲ 104.5% | -43.7M▼ 337.9% | -54.73M▼ 25.2% | -19.7M▲ 0% |
Operating Margin % | -22.15% | -43.27% | -74.57% | -87.12% | -92.19% | -96.1% | 2.19% | -6.94% | -9.95% | -3.27% |
Operating Income Growth % | -14.39% | -73.43% | -64.92% | -30% | -65.3% | -24.81% | 104.48% | -337.85% | -25.22% | - |
EBITDA | -50.84M | -89.05M | -147.84M | -192.56M | -321.13M | -401.11M | 26.58M | -31.36M | -41.38M | -7.49M |
EBITDA Margin % | -21.08% | -41.59% | -72.16% | -84.46% | -90.17% | -94.07% | 3.17% | -4.98% | -7.52% | -1.24% |
EBITDA Growth % | -14.52% | -75.16% | -66.02% | -30.25% | -66.77% | -24.91% | 106.63% | -217.99% | -31.94% | 93.2% |
D&A (Non-Cash Add-back) | 2.58M | 3.59M | 4.94M | 6.06M | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M | 12.21M |
EBIT | -52.08M | -85.65M | -140.07M | -198.62M | -215.15M | -409.77M | 18.38M | -43.7M | -54.73M | -19.7M |
Net Interest Income | -235K | 4.97M | 3.91M | 2.45M | 1.48M | 8.95M | 35.39M | 37.21M | 47.14M | 37.21M |
Interest Income | 1.22M | 5.98M | 4.94M | 3.24M | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M | 37.21M |
Interest Expense | 1.46M | 1.01M | 1.03M | 787K | 592K | 652K | 759K | 2.87M | 2.87M | 0 |
Other Income/Expense | 33.53M | 25.32M | 52.2M | 87.74M | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M | 554.73M |
Pretax Income | -19.88M▲ 0% | -67.32M▼ 238.6% | -100.58M▼ 49.4% | -110.88M▼ 10.2% | -155.33M▼ 40.1% | -360.24M▼ 131.9% | 105.6M▲ 129.3% | 45.36M▼ 57.0% | 522.72M▲ 1052.3% | 535.03M▲ 0% |
Pretax Margin % | -8.24% | -31.44% | -49.09% | -48.64% | -43.62% | -84.48% | 12.6% | 7.2% | 95.05% | 88.85% |
Income Tax | 3.08M | 3.96M | 3.27M | 4.83M | 11.92M | -283K | 4.51M | 7.19M | 63.78M | 67.47M |
Effective Tax Rate % | -15.49% | -5.89% | -3.26% | -4.36% | -7.67% | 0.08% | 4.27% | 15.85% | 12.2% | 12.61% |
Net Income | -26.74M▲ 0% | -74.81M▼ 179.8% | -106.02M▼ 41.7% | -125.73M▼ 18.6% | -194.65M▼ 54.8% | -360.83M▼ 85.4% | 100.78M▲ 127.9% | 37.73M▼ 62.6% | 458.12M▲ 1114.2% | 466.88M▲ 0% |
Net Margin % | -11.08% | -34.94% | -51.75% | -55.15% | -54.66% | -84.62% | 12.03% | 5.99% | 83.3% | 77.53% |
Net Income Growth % | -328.56% | -179.78% | -41.73% | -18.59% | -54.81% | -85.38% | 127.93% | -62.56% | 1114.23% | 1212.42% |
Net Income (Continuing) | -22.96M | -71.29M | -103.68M | -115.52M | -167.04M | -360.39M | 101.09M | 38.17M | 458.94M | 467.56M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 23.23M | 23.26M | 24.89M | 34.83M | 52.62M | 26.5M | 12.85M | 11.92M | 13.34M | 12.86M |
EPS (Diluted) | -0.22▲ 0% | -0.55▼ 150.0% | -0.80▼ 45.5% | -0.90▼ 12.5% | -1.25▼ 38.9% | -2.15▼ 72.0% | 0.60▲ 127.9% | 0.22▼ 63.3% | 2.60▲ 1081.8% | 2.68▲ 0% |
EPS Growth % | -324.49% | -150% | -45.45% | -12.5% | -38.89% | -72% | 127.91% | -63.33% | 1081.82% | 1165.87% |
EPS (Basic) | -0.22 | -0.55 | -0.80 | -0.90 | -1.25 | -2.15 | 0.60 | 0.22 | 2.65 | - |
Diluted Shares Outstanding | 123.43M | 132.85M | 133.14M | 139.59M | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M | 174.51M |
Basic Shares Outstanding | 123.43M | 132.85M | 133.14M | 139.59M | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M | 174.98M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
HCM Balance Sheet
HUTCHMED (China) Limited (HCM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 432.19M | 370.54M | 317.02M | 530.74M | 1.21B | 839.89M | 1.1B | 1.07B | 1.57B | 1.59B |
Cash & Short-Term Investments | 358.3M | 300.95M | 217.17M | 435.18M | 1.01B | 631M | 886.34M | 836.11M | 1.37B | 1.36B |
Cash Only | 85.27M | 86.04M | 121.16M | 235.63M | 377.54M | 313.28M | 283.59M | 153.96M | 71.33M | 1.36B |
Short-Term Investments | 273.03M | 214.91M | 96.01M | 199.55M | 634.16M | 317.72M | 602.75M | 682.15M | 1.3B | 1.25B |
Accounts Receivable | 57.25M | 43.85M | 77.17M | 47.87M | 147.73M | 126.72M | 150.46M | 167.74M | 147.83M | 146.97M |
Days Sales Outstanding | 86.63 | 74.75 | 137.48 | 76.64 | 151.41 | 108.47 | 65.53 | 97.15 | 98.11 | 93.53 |
Inventory | 11.79M | 12.31M | 16.21M | 19.77M | 35.76M | 56.69M | 50.26M | 50.4M | 41.13M | 48.45M |
Days Inventory Outstanding | 24.47 | 31.21 | 36.94 | 38.27 | 50.54 | 66.51 | 47.72 | 52.73 | 44.51 | 32.9 |
Other Current Assets | 1.37M | 8.33M | 2.71M | 20.89M | 2.76M | 3.15M | 2.68M | 3.3M | 2.77M | 80.84M |
Total Non-Current Assets | 165.74M | 161.58M | 148.1M | 193.38M | 160.59M | 189.56M | 182.93M | 207.64M | 185.76M | 183.61M |
Property, Plant & Equipment | 15.48M | 17.79M | 27.48M | 45.31M | 66.32M | 84.67M | 104.39M | 97M | 97.65M | 94.57M |
Fixed Asset Turnover | 15.58x | 12.04x | 7.46x | 5.03x | 5.37x | 5.04x | 8.03x | 6.50x | 5.63x | 6.29x |
Goodwill | 3.31M | 3.19M | 3.11M | 3.31M | 3.38M | 3.14M | 3.06M | 2.99M | 3.11M | 0 |
Intangible Assets | 430K | 347K | 275K | 227K | 163K | 3.22M | 21K | 0 | 8.94M | 0 |
Long-Term Investments | 144.24M | -76.6M | 2.93M | -60.04M | -557.68M | -243.94M | 48.41M | -599.39M | 52.25M | -499.33M |
Other Non-Current Assets | 1.65M | 216.27M | 113.48M | 203.06M | 639M | 327.1M | 11.59M | 707.04M | 11.15M | 80.39M |
Total Assets | 597.93M▲ 0% | 532.12M▼ 11.0% | 465.12M▼ 12.6% | 724.12M▲ 55.7% | 1.37B▲ 89.6% | 1.03B▼ 25.0% | 1.28B▲ 24.3% | 1.27B▼ 0.4% | 1.75B▲ 37.6% | 1.78B▲ 0% |
Asset Turnover | 0.40x | 0.40x | 0.44x | 0.31x | 0.26x | 0.41x | 0.65x | 0.49x | 0.31x | 0.39x |
Asset Growth % | 74.61% | -11.01% | -12.59% | 55.68% | 89.56% | -25% | 24.32% | -0.44% | 37.59% | 80.83% |
Total Current Liabilities | 104.6M | 85.48M | 113.1M | 158.4M | 311.66M | 353.9M | 403.03M | 376.56M | 315.78M | 342.41M |
Accounts Payable | 24.36M | 25.63M | 23.96M | 31.61M | 41.18M | 71.11M | 36.33M | 42.52M | 45.53M | 43.73M |
Days Payables Outstanding | 50.58 | 64.98 | 54.61 | 61.21 | 58.2 | 83.44 | 34.49 | 44.49 | 49.28 | 28.7 |
Short-Term Debt | 31.99M | 432K | 366K | 3.19M | 26.91M | 3.71M | 31.16M | 23.37M | 27.85M | 25.6M |
Deferred Revenue (Current) | 2.58M | 2.54M | 2.11M | 1.6M | 15.55M | 13.35M | 57.64M | 0 | 31.42M | 0 |
Other Current Liabilities | 9.34M | 8.43M | 8.09M | 8.47M | 40.95M | 37.39M | 228.93M | 290.08M | 176.94M | 47.93M |
Current Ratio | 4.13x | 4.33x | 2.80x | 3.35x | 3.89x | 2.37x | 2.72x | 2.83x | 4.96x | 4.65x |
Quick Ratio | 4.02x | 4.19x | 2.66x | 3.23x | 3.77x | 2.21x | 2.60x | 2.70x | 4.83x | 4.51x |
Cash Conversion Cycle | 60.52 | 40.98 | 119.81 | 53.71 | 143.75 | 91.55 | 78.76 | 105.4 | 93.34 | 97.72 |
Total Non-Current Liabilities | 8.37M | 34.38M | 39.12M | 46.77M | 21.49M | 38.67M | 133.36M | 125.78M | 186.06M | 191.6M |
Long-Term Debt | 579K | 27.32M | 26.82M | 26.86M | 0 | 18.1M | 48.19M | 59.43M | 68.19M | 93.44M |
Capital Lease Obligations | 0 | 0 | 3.05M | 6.06M | 7.16M | 5.2M | 2.86M | 4.09M | 1.85M | 14.56M |
Deferred Tax Liabilities | 4.45M | 4.84M | 3.16M | 5.06M | 2.77M | 2.71M | 1.48M | 2.99M | 255K | 2.99M |
Other Non-Current Liabilities | 538K | 280K | 5.96M | 8.3M | 14.33M | 12.47M | 11.35M | 10.84M | 95.63M | 98.16M |
Total Liabilities | 112.97M | 119.86M | 152.22M | 205.17M | 333.15M | 392.57M | 536.39M | 502.34M | 501.84M | 534.02M |
Total Debt | 32.57M | 27.75M | 33.45M | 38.9M | 38.98M | 27.01M | 86.13M | 89.82M | 97.89M | 100.73M |
Net Debt | -52.7M | -58.29M | -87.71M | -196.73M | -338.56M | -286.27M | -197.46M | -64.14M | 26.56M | -9.99M |
Debt / Equity | 0.07x | 0.07x | 0.11x | 0.07x | 0.04x | 0.04x | 0.12x | 0.12x | 0.08x | 0.08x |
Debt / EBITDA | - | - | - | - | - | - | 3.24x | - | - | -13.45x |
Net Debt / EBITDA | - | - | - | - | - | - | -7.43x | - | - | 1.33x |
Interest Coverage | -35.79x | -84.88x | -136.00x | -252.37x | -363.43x | -628.48x | 24.21x | -15.22x | -19.05x | - |
Total Equity | 484.97M▲ 0% | 412.25M▼ 15.0% | 312.9M▼ 24.1% | 518.95M▲ 65.8% | 1.04B▲ 100.3% | 636.87M▼ 38.7% | 743.39M▲ 16.7% | 771.85M▲ 3.8% | 1.25B▲ 62.1% | 1.24B▲ 0% |
Equity Growth % | 137.66% | -14.99% | -24.1% | 65.85% | 100.31% | -38.73% | 16.73% | 3.83% | 62.11% | 137.95% |
Book Value per Share | 3.93 | 3.10 | 2.35 | 3.72 | 6.56 | 3.76 | 4.28 | 4.42 | 7.17 | 7.12 |
Total Shareholders' Equity | 461.73M | 389M | 288.01M | 484.12M | 986.89M | 610.37M | 730.54M | 759.93M | 1.24B | 1.23B |
Common Stock | 66.45M | 66.66M | 66.69M | 72.77M | 86.45M | 86.48M | 87.13M | 87.16M | 87.23M | 87.21M |
Retained Earnings | -107.1M | -183M | -289.73M | -415.59M | -610.33M | -971.48M | -870.87M | -833.17M | -378.64M | -380.32M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 5.43M | -243K | -3.85M | 4.48M | 5.57M | -1.9M | -8.16M | -11.59M | -4.53M | -5.49M |
Minority Interest | 23.23M | 23.26M | 24.89M | 34.83M | 52.62M | 26.5M | 12.85M | 11.92M | 13.34M | 12.86M |
HCM Cash Flow Statement
HUTCHMED (China) Limited (HCM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.94M | -32.85M | -80.91M | -62.07M | -204.22M | -268.6M | 219.26M | 497K | -64.83M | -32.56M |
Operating CF Margin % | -3.71% | -15.34% | -39.49% | -27.22% | -57.35% | -62.99% | 26.16% | 0.08% | -11.79% | - |
Operating CF Growth % | 6.54% | -267.29% | -146.33% | 23.29% | -229.04% | -31.52% | 181.63% | -99.77% | -13143.86% | 1162.87% |
Net Income | -22.96M | -71.29M | -103.68M | -115.52M | -167.04M | -360.39M | 100.78M | 37.73M | 458.12M | 466.88M |
Depreciation & Amortization | 2.58M | 3.59M | 4.94M | 6.06M | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M | 12.21M |
Stock-Based Compensation | 4.74M | 10.13M | 11.59M | 19.64M | 41.99M | 30.59M | 36.6M | 21.61M | 15.29M | 17.99M |
Deferred Taxes | 20.82M | 17.68M | -10.27M | 552K | -115.14M | 0 | -102.76M | 0 | 0 | 0 |
Other Non-Cash Items | -11.68M | 895K | 394K | -2.08M | -3.68M | -6.17M | 105.28M | -9.01M | -490.56M | -497.11M |
Working Capital Changes | -2.44M | 6.14M | 16.11M | 29.27M | 32.46M | 58.7M | 71.15M | -62.17M | -61.02M | -32.53M |
Change in Receivables | 2.52M | -486K | -553K | -4.69M | -35.63M | -14.45M | -21.34M | -41.57M | 28.94M | 9.93M |
Change in Inventory | 1.05M | -557K | -4.21M | -3.62M | -16M | -21.21M | 4.13M | -772K | 9.57M | -2.31M |
Change in Payables | 0 | 0 | -1.66M | 7.65M | 9.56M | 29.94M | -32.54M | 0 | 3.02M | 0 |
Cash from Investing | -260.78M | 43.75M | 119.03M | -125.44M | -306.32M | 296.59M | -291.14M | -96.06M | -29.49M | -73.03M |
Capital Expenditures | -5.02M | -6.36M | -8.56M | -19.58M | -16.76M | -36.66M | -32.61M | -17.93M | -24.21M | -17.09M |
CapEx % of Revenue | 2.08% | 2.97% | 4.18% | 8.59% | 4.71% | 8.6% | 3.89% | 2.85% | 4.4% | 2.84% |
Acquisitions | 0 | 0 | 8.69M | 0 | 159.12M | 324K | -2.99M | 0 | 28.07K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -2.33M | 930K | 16.49M | 29.5M | 1.28M | 0 | -55.94M |
Cash from Financing | 273.2M | -8.23M | -1.49M | 296.43M | 650.03M | -82.76M | 48.66M | -30.67M | 7.86M | 11.22M |
Debt Issued (Net) | -16.95M | -3.08M | -182K | 35.06K | -579.77K | -9.17M | 61.7M | 5.61M | 6.27M | 0 |
Equity Issued (Net) | 291.74M | -1.58M | -346K | 306.03M | 690.01M | -47.91M | -3.98M | -35.27M | 1.58M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | -99.74M | -87.44M | 0 | 0 | 0 | 0 |
Share Repurchases | -1.37M | -5.45M | -346K | -12.9M | -27.31M | -48.08M | -9.07M | -36.06M | 0 | 0 |
Other Financing | -1.59M | -3.57M | -965K | -9.63M | 60.34M | 61.75M | -9.07M | -1M | 0 | 11.22M |
Net Change in Cash | 5.83M▲ 0% | 771K▼ 86.8% | 35.12M▲ 4455.3% | 114.47M▲ 225.9% | 141.91M▲ 24.0% | -64.26M▼ 145.3% | -29.69M▲ 53.8% | -129.63M▼ 336.6% | -82.63M▲ 36.3% | -203.95M▲ 0% |
Free Cash Flow | -13.96M▲ 0% | -39.21M▼ 180.8% | -89.48M▼ 128.2% | -81.65M▲ 8.8% | -220.98M▼ 170.7% | -305.26M▼ 38.1% | 186.65M▲ 161.1% | -17.44M▼ 109.3% | -79.01M▼ 353.2% | -49.66M▲ 0% |
FCF Margin % | -5.79% | -18.31% | -43.67% | -35.81% | -62.05% | -71.59% | 22.27% | -2.77% | -14.37% | -8.25% |
FCF Growth % | -0.47% | -180.84% | -128.19% | 8.75% | -170.66% | -38.14% | 161.14% | -109.34% | -353.16% | 24% |
FCF per Share | -0.11 | -0.30 | -0.67 | -0.58 | -1.39 | -1.80 | 1.07 | -0.10 | -0.45 | -0.28 |
FCF Conversion (FCF/Net Income) | 0.33x | 0.44x | 0.76x | 0.49x | 1.05x | 0.74x | 2.18x | 0.01x | -0.14x | -0.11x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.51M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HCM Key Ratios
HUTCHMED (China) Limited (HCM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -7.76% | -16.67% | -29.24% | -30.23% | -24.98% | -43.05% | 14.6% | 4.98% | 45.29% | 46.37% |
Return on Invested Capital (ROIC) | -13.05% | -17.67% | -39.57% | -54.42% | -48.13% | -58.45% | 3.07% | -5.23% | -4.13% | -2.25% |
Gross Margin | 27.11% | 32.77% | 21.84% | 17.31% | 27.49% | 27.04% | 54.12% | 44.64% | 38.68% | 8.93% |
Net Margin | -11.08% | -34.94% | -51.75% | -55.15% | -54.66% | -84.62% | 12.03% | 5.99% | 83.3% | 77.53% |
Debt / Equity | 0.07x | 0.07x | 0.11x | 0.07x | 0.04x | 0.04x | 0.12x | 0.12x | 0.08x | 0.08x |
Interest Coverage | -35.79x | -84.88x | -136.00x | -252.37x | -363.43x | -628.48x | 24.21x | -15.22x | -19.05x | - |
FCF Conversion | 0.33x | 0.44x | 0.76x | 0.49x | 1.05x | 0.74x | 2.18x | 0.01x | -0.14x | -0.11x |
Revenue Growth | 11.63% | -11.23% | -4.31% | 11.27% | 56.21% | 19.73% | 96.52% | -24.8% | -12.73% | -1.41% |
Related:HCM Dividend History·HCM Revenue History·HCM Price History·HCM P/E History·HCM Financial Ratios·HCM Institutional Holders
HCM Frequently Asked Questions
HUTCHMED (China) Limited (HCM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
HUTCHMED (China) Limited (HCM) reported $602.2M in revenue for fiscal year 2025. This represents a 1491% increase from $37.9M in 2005.
HUTCHMED (China) Limited (HCM) saw revenue decline by 12.7% over the past year.
Yes, HUTCHMED (China) Limited (HCM) is profitable, generating $466.9M in net income for fiscal year 2025 (83.3% net margin).
Dividend & Returns
HUTCHMED (China) Limited (HCM) has a return on equity (ROE) of 45.3%. This is excellent, indicating efficient use of shareholder capital.
HUTCHMED (China) Limited (HCM) had negative free cash flow of $49.7M in fiscal year 2025, likely due to heavy capital investments.